Viking Therapeutics Inc. is enduring a tumultuous financial period as it faces a projected 222.73% decline in year-over-year earnings, with analysts assigning it a Zacks Rank of #4 (Sell). The company's stock has dropped to $25.09 following a disappointing forecast for its investigational obesity drug VK2735. Despite previous enthusiasm for the drug’s potential in Phase 2 and Phase 3 studies, the market reaction reflects ongoing investor uncertainty amid warnings from notable financial analysts. As Viking prepares for critical trial results and navigates buyout speculation, its future hinges on the success of VK2735 in the highly competitive obesity treatment landscape.
Click a month on the chart to update the report below.